Tirzepatide

Tirzepatide be an antidiabetic medication dem use to treat type2 diabetes den for weight loss. Dem dey administer tirzepatide via subcutaneous injections (under de skin). Insyd de United States, dem dey sell under de brand name Mounjaro for diabetes treatment den Zepbound for weight loss den treatment of obstructive sleep apnea.

Tirzepatide be a gastric inhibitory polypeptide (GIP) analog den a GLP-1 receptor agonist. De most common side effects dey include nausea, vomiting, diarrhea, decreased appetite, constipation, upper abdominal discomfort, den abdominal pain.

Eli Lilly and Company develop am, na dem approve tirzepatide for treatment of diabetes insyd de U.S. insyd May 2022, insyd de European Union insyd September 2022, insyd Canada insyd November 2022, den insyd Australia insyd December 2022. De U.S. Food and Drug Administration (FDA) dey consider am a first-in-class medication. Na de FDA approve am for weight loss insyd November 2023. Also insyd November 2023, de U.K. Medicines and Healthcare products Regulatory Agency revise de indication for tirzepatide (as Mounjaro) to include de treatment for weight management den weight loss. Insyd December 2024, na de FDA revise de indication for tirzepatide (as Zepbound) to include de treatment of moderate to severe obstructive sleep apnea. Insyd 2023, na tirzepatide be de 110th-most commonly prescribed medication insyd de U.S., plus more dan six million prescriptions.

 References 
Category:Translated from MDWiki

 External links 

Category:Drugs wey Eli Lilly and Company develop
Category:Anti-obesity drugs
Category:GLP-1 receptor agonists
Category:GIP receptor agonists
Category:Hormones of de digestive system
Category:Neuropeptides
Category:Peptide hormones
Category:Peptide therapeutics
Category:Lipopeptides